A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Completed · Phase 3 · NCT04666610
Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy
At a glance
- Research payments reported, 2025
- $209,410
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 154
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Brivaracetam (drug), Placebo (other)
- Dates
- Started 2021-07-29; completion 2026-07-07
- Results posted
- Not yet
The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
From ClinicalTrials.gov, last updated 2026-10-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $209,410 in research payments for this study in 2025 (7 payments).
Products named: Briviact
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Pongkiat Kankirawatana, M.D. Child Neurology · Birmingham, AL
- Donald J. Phillips, M.D. Neurology · Orange, CA
- Andrew White, MD Neurology · Denver, CO
- Anuj Jayakar, MD Child Neurology · Miami, FL
- Yong D. Park, MD Child Neurology · Augusta, GA
- Gautam S. Popli, M.D. Child Neurology · Winston Salem, NC
- Carlos Lastra, M.D. Child Neurology · New Brunswick, NJ
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Alabama Hospital, AL $121,144
- Nicklaus Children's Hospital, FL $49,672
- Denver Health & Hospital Authority, CO $12,700
- Ghsu Research Institute, Inc. $10,314
- Children's Hospital of Orange County, CA $10,097
- Saint Peter's University Hospital, NJ $3,000
- Wake Forest University Health Sciences $2,483
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.